Table 2.
Baseline factors of patients with neovascular age-related macular degeneration aged ≥90 years enrolled in Aflibercept or Ranibizumab treatment, which remained in treatment for at least the follow-up after the loading dose phase.
| Aflibercept (n = 49) | Ranibizumab (n = 57) | P value | |
|---|---|---|---|
| Age, years, median (IQR) | 91 (90 to 93) | 91 (90 to 92) | 0.400 |
| Gender, n (%) | 0.370 | ||
| Female | 35 (71) | 45 (79) | |
| Male | 14 (29) | 12 (21) | |
| BCVA, ETDRS letters, mean (SD) | 50 (14) | 48 (18) | 0.510 |
| Average CRT, mean (SD) | 433 (130) | 445 (114) | 0.660 |
| Lesion type, n (%)† | 0.309 | ||
| Predominantly classic | 16 (35) | 18 (34) | |
| Predominantly occult | 25 (54) | 34 (64) | |
| Retinal angiomatous proliferation | 5 (11) | 1 (2) |
IQR: interquartile range; SD: standard deviation; BCVA: best-corrected visual acuity; CRT: central retinal thickness.†No data on lesion type for three patients in the Aflibercept group and four patients in the Ranibizumab group due to allergies to the contrast agents, lack of cooperation, or inaccessible data. P values were calculated using the Mann–Whitney U test for age, χ2-test for gender, independent samples t-test for BCVA and average CRT, and Fisher's exact test for lesion type due to groups with <5.